Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picroliv in Non-Alcoholic Fatty Liver Disease
NCT07452744Phase 3Enrolling by invitation
- Sponsor
- BioAgile Therapeutics Pvt. Ltd.
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of picroliv in non-alcoholic fatty liver disease (NAFLD), sponsored by BioAgile Therapeutics Pvt. Ltd. Primary endpoint: Change in hepatic fat fraction at 24 weeks. Started Aug 2024; status: enrolling by invitation.
02
Drugs
picroliv
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07452744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452744.